EDAP Highlights Innovative Sonolith i-move Lithotripter at the Annual Japanese Urological Association Meeting
21 April 2011 - 12:09AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today the demonstration of its full range of
innovative lithotripsy devices at the 99th Annual Meeting of the
Japanese Urological Association (J.U.A.) (booth #14), held April 21
- 24, 2011 in Nagoya, Japan.
Japan is one of the largest global urology markets with the
highest number of installed lithotripsy devices. EDAP is
committed to gaining market share in the Japanese territory by
successfully introducing its innovative high-end Sonolith range of
lithotripters. The Sonolith i-move will be officially introduced at
the JUA to the Japanese Urology Community, for which expectations
are high for innovations and technological breakthroughs in
lithotripsy. Sonolith i-move lithotripter is in the clearance
application process, currently under review by the Japanese
Administration.
EDAP will also take this major event opportunity to officially
launch the distribution in Japan of Medical Measurement Systems
B.V. (MMS)' urodynamics diagnostic products. With this exclusive
agreement, EDAP becomes the leader in urodynamics devices in the
Japanese territory.
Jean-François Bachelard, President and CEO of EDAP TMS's
subsidiary in Japan, commented, "The lithotripsy global market
remains dynamic and we will leverage on our growth in lithotripsy
activity by continuing expansion in the Japan. We strongly believe
that the Sonolith i-move, with its unique infrared-vision
localization system, perfectly suits the Japanese market needs.
Hence, it will be aggressively positioned in the market to first
replace most of our current Sonolith Praktis models installed in
Japan and, second, it will allow us to take market share from
competition as we successfully did in Europe."
Marc Oczachowski, EDAP TMS's Chief Executive Officer, continued,
"EDAP has made a long term commitment in Japan as exemplified by
its direct presence over the past fifteen years and its expanded
sales force that is part of the entity's 30 person team. We will
continue to focus on developing innovative and state-of-the-art
treatment approaches in the urology field to further address a
significant market potential."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multi-center U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. These include statements regarding the Company's
growth and expansion plans, the conclusiveness of the results of
and success of its Ablatherm-HIFU clinical trials and expectations
regarding the IDE submission to and approval by the FDA of the
Ablatherm-HIFU device. Such statements are based on management's
current expectations and are subject to a number of uncertainties,
including the uncertainties of the regulatory process, and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical
trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024